Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 517 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR Answers to Your Questions About the COVID-19 Vaccine March 4, 2021 Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced... August 30, 2024 Mark Hoppus Of Blink-182 Announces He’s Cancer-Free October 8, 2021 Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... February 13, 2022 Load more HOT NEWS Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... ESMO Breast Cancer Virtual Congress 2021, 5-8 May To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome Online Retailer Chastised for Claiming Their Bra Reduces Risk of Breast...
